The plasma fractionation market is expected to experience growth, with some reports indicating a compound annual growth rate (cagr) of 7.3% through 2032. The market's size is projected to reach varying values by 2032, including $51.06 billion and $52.82 billion, driven by factors such as rising demand for immunoglobulins and plasma-derived therapies. The related blood plasma market is also expected to grow, with one estimate valuing it at $79.5 million by 2032.